Rocket Pharmaceuticals Inc (RCKT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Rocket Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.10 $ — 19% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 202.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 18
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.75 | -1.98 – -0.12 | 17 | 62.2% | 6 |
| 12/31/2027 | -1.18 | -1.88 – -0.12 | 20 | -57.4% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.28 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.62 | – | 9 | -10.90 | -656.70 | -47 | -47 |
| 2025: Q1 | -0.56 | – | 0 | – | – | -56 | -56 |
| 2025: Q2 | -0.62 | – | 0 | – | – | -49 | -49 |
| 2025: Q3 | -0.45 | – | 0 | – | – | -50 | -50 |
| 2025: Q4 | -0.38 | – | 0 | -100.00 | – | -35 | -35 |
| 2026: Q1 | -0.42 | – | 0 | – | – | -45 | -46 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -42 | -43 | -6.41 | -37 | 73 | 130 |
| 2017 | 0 | -27 | -30 | -4.36 | -26 | 48 | 102 |
| 2018 | 0 | -71 | -75 | -1.89 | -54 | 194 | 251 |
| 2019 | 0 | -76 | -83 | -1.70 | -65 | 307 | 372 |
| 2020 | 0 | -136 | -147 | -2.65 | -75 | 504 | 591 |
| 2021 | 0 | -167 | -169 | -2.67 | -121 | 455 | 497 |
| 2022 | 0 | -224 | -222 | -3.26 | -178 | 490 | 552 |
| 2023 | 0 | -260 | -246 | -2.92 | -195 | 493 | 566 |
| 2024 | 0 | -273 | -259 | -2.73 | -210 | 463 | 528 |
| 2025 | 0 | -229 | -223 | -2.01 | -190 | 277 | 330 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Rocket Pharmaceuticals, Inc. , together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
| Employees | 202 |
|---|---|
| Headquarters | Cranbury, NJ |
| Address | 9 Cedarbrook Drive, 08512 Cranbury, United States |
| Phone | 609 659 8001 |
| Website | rocketpharma.com |
| IPO Date | 18. Feb 2015 |
| ISIN | US77313F1066 |
| Stock Split | 1:4 on 01/05/2018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gaurav D. Shah M.D. | CEO & Director | 1975 |
| Martin Louis Wilson J.D. | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer | 1976 |
| Christopher Stevens | Chief Operating Officer | 1981 |
| Joseph Manhede | Principal Accounting Officer | 1978 |
| Jonathan Schwartz M.D. | Chief Science & Gene Therapy Officer | 1965 |
| Meg Dodge J.D., L.L.M. | Senior Vice President & Head of External Affairs | – |
| Sarbani Chaudhuri M.B.A. | Chief Commercial & Medical Affairs Officer | 1975 |
| Syed Ali-Aamir Rizvi M.D. | Chief Medical Officer | 1967 |
| Kevin Giordano | Director of Corporate Communications | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.